The Future of EGFR-Mutant NSCLC: Antibody-Drug Conjugates & Combination Therapies
In this episode of OncoDaily, Dr. Jordi Ramon from Gustave-Roussy discusses the management of EGFR-mutant non-small cell lung cancer. He highlights the current use of third-generation EGFR TKIs and anticipates future combinations with chemotherapy or other agents. He also addresses the importance of managing resistance and the role of antibody-drug conjugates. Targeted therapies are now standard across all disease stages, including adjuvant settings, with promising results from the LOWER trial showing the benefits of osimertinib in stage III disease. Abstract:- https://doi.org/10.1200/JCO.23.01521 SUBSCRIBE to get the latest #oncodaily / @oncodailytv Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn: / oncodaily Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram: / oncodailynews Follow OncoDaily on TikTok: / oncodaily Like OncoDaily on Facebook: / oncodaily SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of #OncoDaily is “Cancer doesn’t take a day off – neither do we.” Learn the current standard of care for non-small cell lung cancer patients with EGFR mutations. Medical oncologist Dr. Jordi Ramon breaks down treatment protocols. This session focuses on the clinical management of NSCLC cases involving specific genomic alterations. Dr. Ramon explains why EGFR mutation treatment requires a targeted approach, noting that these mutations appear in approximately 15% of patients, with higher prevalence rates observed in individuals of Asian ethnicity. We review the shift toward third-generation EGFR inhibitors as the primary standard of care for these patients. Whether you are a medical professional or seeking a clear understanding of current lung cancer oncology practices, this overview provides the essential clinical context for managing these specific diagnoses. Subscribe for weekly #oncology treatment breakdowns, and comment below on which cancer subtypes you would like us to cover next.
